By recognizing that the key to remaining at the forefront of technological know-how requires housing the best and brightest corporate and scientific minds, IntelliPharmaCeutics will continue to make history in its unprecedented growth and delivery in the global pharmaceutical market.

Our Chief Scientists, Dr. Isa Odidi and Dr. Amina Odidi, are the inventors of each of IntelliPharmaCeutics’ groundbreaking core drug delivery technologies. They were also directly responsible for the design, development and advancement to production scale of each of ten FDA-approved and commercially successful drugs and dosage strengths now on sale in the United States.

Drs. Isa and Amina Odidi have also played key roles in the administration of IntelliPharmaCeutics’ success to date. Their management capability in the scientific area of the business is built on experience at highest level of drug development. Prior to the formation of IntelliPharmaCeutics, Dr. Isa Odidi was a Vice President and the Chief Scientific Officer at Biovail Corporation. In only three years there, from 1995 through 1998, he was the person primarily responsible for establishing and managing the R&D facility.

“From IntelliPharmaCeutics' inception to its present status as a high value-added company, management has put in place systems in which science flourishes while cash resources are wisely deployed. As the management and scientific teams are built out, these principles will remain strong:

	Management will run the company to maximize the potential for science-fuelled growth; and
	Scientific Staff will conduct their research and development with an eye on measurable output and value.

The extensive experience and accomplishments of each of Intellipharmaceutics Corp. Directors can be reviewed by clicking on their individual names.”